Researchers from Integra Therapeutics, in partnership with the Pompeu Fabra University (UPF) and the Centre for Genomic Regulation (CRG), Spain, have used generative AI to design synthetic proteins that outperform naturally occurring proteins used for editing the human genome. Their use of generative AI focused on PiggyBac transposases, naturally occurring enzymes that have long been used for gene delivery and genetic engineering, and uncovered more than 13,000 previously unidentified PiggyBac sequences. The research, published in Nature Biotechnology, has the potential to improve current gene editing tools for the creation of CAR T and gene therapies.
“Our work expands the phylogenetic tree of PiggyBac transposons by two orders of magnitude, unveiling a previously unexplored diversity within this family of mobile genetic elements,” the researchers wrote.
For their work, the researchers first conducted extensive computational bioprospecting, screening more than 31,000 eukaryotic genomes to uncover the 13,000 new sequences. From this number, the team was able to validate 10 active transposases, two of which showed similar activity to PiggyBac transposases currently used in both research and clinical settings.